Misplaced Pages

Richard Sykes (microbiologist): Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 22:03, 18 April 2009 editTravisAF (talk | contribs)Rollbackers1,453 editsm Reverted edits by 90.211.247.2 to last revision by 90.208.100.180 (HG)← Previous edit Latest revision as of 09:42, 7 October 2024 edit undoGooglerW (talk | contribs)Extended confirmed users1,629 editsm ce 
(474 intermediate revisions by more than 100 users not shown)
Line 1: Line 1:
{{Short description|British microbiologist (born 1942)}}
{{otheruses|Richard Sykes}}
{{Use dmy dates|date=August 2023}}
] '''Richard "Dick" Sykes''', ], ], ], ] (born 1942) is a biochemist and former executive in a number of pharmaceuticals, most notably ].
{{Use British English|date=May 2012}}
{{Infobox scientist
| honorific_prefix = Sir
| name = Richard Sykes
| honorific_suffix = {{post-nominals|country=GBR|size=100%|FRS|FMedSci|HonFREng}}
| native_name =
| native_name_lang =
| image = <!--(filename only, i.e. without "File:" prefix)-->
| image_size =
| image_upright =
| alt =
| caption =
| birth_name = Richard Brook Sykes
| birth_date = {{birth date and age|df=yes|1942|08|07}}
| birth_place = ], West Yorkshire, England
| death_date = <!--{{death date and age |YYYY|MM|DD |YYYY|MM|DD}} (death date then birth date)-->
| death_place =
| death_cause =
| resting_place =
| resting_place_coordinates = <!--{{coord|LAT|LONG|type:landmark|display=inline,title}}-->
| other_names =
| siglum =
| pronounce =
| citizenship = <!-- use only when necessary per ] -->
| nationality = <!-- use only when necessary per ] -->
| education = {{plainlist|
* ] (])
* ] (])
* ] (DSc)}}
| fields = {{plainlist|
* ]
* ]}}
| workplaces = {{Indented plainlist|
* ]
* ]
* ]
* ]
* ]
* ]
* ]
* Brunel University
* ]
* ]}}
| patrons =
| thesis_title = <!--(or | thesis1_title = and | thesis2_title = )-->
| thesis_url = <!--(or | thesis1_url = and | thesis2_url = )-->
| thesis_year = <!--(or | thesis1_year = and | thesis2_year = )-->
| doctoral_advisor = <!--(or | doctoral_advisors = )-->
| academic_advisors =
| doctoral_students =
| notable_students =
| known_for = {{plainlist|* ] (1981)
*Formation of ] (1995)
*Formation of ] (2000)
*] (2001–2008)
*Chair of ] (2010)}}
| influences =
| influenced =
| awards = {{plainlist|
* ] (1994)
* ] (2009)}}
| author_abbrev_bot =
| author_abbrev_zoo =
| spouse = <!--(or | spouses = )-->
| partner = <!--(or | partners = )-->
| children =
| parents =
| father =
| mother =
| relatives =
| signature = <!--(filename only)-->
| signature_alt =
| website = <!--{{URL|www.example.com}}-->
| footnotes =
| module = {{Infobox officeholder | embed = yes
| office = Chair of the ]
| term_start = 2021
| term_end =
}}
}}
'''Sir Richard Brook Sykes''' {{post-nominals|country=GBR|size=100%|FRS|FMedSci|HonFREng}} (born 7 August 1942) is a British ], the chair of the ], the UK Stem Cell Foundation, and the trustees at ], and ] of ]. As of June 2021, he is chair of the UK's ], where he is responsible for overseeing the delivery of the ], including preparations for booster programmes and encouraging vaccine innovation in the UK.


In 1972, after gaining a first class ] degree and a ], both in ], Sykes was appointed head of the Antibiotic Resistance Unit at ], where he helped develop the antibiotic ]. Subsequently, he was recruited by the ], in the United States, where he then developed ], the first clinically effective ], a term he coined in 1981 to describe a new group of monocyclic β-lactams produced by bacteria. He oversaw the merger of Glaxo with Wellcome, to form Glaxo-Wellcome in 1995 and became its chair two years later. He then oversaw the ] and held its chair until 2001.


His other appointments have included being ] from 2001 to 2008, chairman of ] from December 2008 to July 2010, vice-chairman of Lonza Group until 2013, and chairman of ] from 2012 to 2018.
==Degrees==
He holds a degree from ], and a ] in Microbial Biochemistry from the ] as well as number of ]s, including ones from the universities of ], ], ], ], ], ], ], ], ], ], ], ], ], ], ], ], ] and ].


==Early life and education==
==Commerce==
Richard Sykes was born in the outskirts of ], in West Yorkshire, on 7 August 1942<ref>{{cite news |url=https://www.theguardian.com/business/2004/jun/20/theobserver.observerbusiness10 |title=Imperial boss measures up money men |first=Heather |last=Connon |date=20 June 2004 |work=The Guardian |access-date=7 August 2023}}</ref> to Eric Sykes and his wife Muriel Mary Sykes.<ref name="WHO2018">{{cite book |title=Who's Who 2018 |date=2018 |publisher=Bloomsbury Publishing |location=London |isbn=978-1-472-93501-4 |page=2380 |edition=170th |url=https://books.google.com/books?id=xeupswEACAAJ |language=en}}</ref><ref name=Wong2005>Wong, John (6 July 2015) . National University of Singapore. Honorary degree of science recipient</ref> He attended ].<ref name="Fletcher2003">{{cite book |last1=Fletcher |first1=Winston |title=Beating the 24/7: How Business Leaders Achieve a Successful Work/Life Balance |date=2003 |publisher=John Wiley & Sons |location=Chichester |isbn=0-470-84762-X |pages=31–40 |url=https://books.google.com/books?id=9zQ-Hy3p9O8C&q=%22richard+sykes%22 |language=en |chapter=1. Sir Richard Sykes FRS}}</ref> Prior to his ] and completing school, he took up a job as a technician in a ] laboratory.<ref name="Lawrence2002">{{cite journal |last1=Lawrence |first1=Rebecca N. |title=Sir Richard Sykes contemplates the future of the pharma industry. Interview by Rebecca N Lawrence |journal=Drug Discovery Today |date=15 June 2002 |volume=7 |issue=12 |pages=645–648 |doi=10.1016/s1359-6446(02)02305-x |pmid=12110238 |url=https://pubmed.ncbi.nlm.nih.gov/12110238/ |issn=1359-6446}}</ref> After leaving secondary school he attended ] and ], and gained a place at ] where he was awarded a first class ] degree in ].<ref name="WHO2018"/> He received his ] in 1972 with a thesis on ] of '']'', from the ], where he worked with ].<ref name="WHO2018"/><ref name="Sykes2010">{{cite journal |last1=Sykes |first1=Richard |title=The 2009 Garrod lecture: the evolution of antimicrobial resistance: a Darwinian perspective |journal=The Journal of Antimicrobial Chemotherapy |date=September 2010 |volume=65 |issue=9 |pages=1842–1852 |doi=10.1093/jac/dkq217 |pmid=20573657 |issn=1460-2091|doi-access=free }}</ref> In 1973, together, they reported the first β-lactamase classification scheme.<ref name="Bittar1998">{{cite book |last1=Cooksey |first1=Robert C. |editor1-last=Bittar |editor1-first=Edward |title=Microbiology |date=1998 |publisher=Elsevier |location=Greenwich, Connecticut |isbn=1-55938-814-5 |page=207 |chapter-url=https://books.google.com/books?id=dMrxONoCS54C&dq=sykes&pg=PA207 |language=en |chapter=13. Mechanisms of resistance to antibacterial agents}}</ref>
Until 2001, Sykes was chairman of ] and president of the ]. In 1994 he was ] for his services to the ] and in 1999 he was awarded the ] for his services to the economy of ]. In December 2007 he was appointed Independent Non-Executive Director at ](ENRC). In October 2008 Sykes accepted ]'s invitation to join the as the non-executive Chairman.


==Imperial College== ==Glaxo and Squibb==
]
Between January 2001 and July 2008, Sykes was the ] of ].
In 1972 Sykes was appointed head of the Antibiotic Resistance Unit at ].<ref name="WHO2018"/><ref name="Goff2007">{{cite journal |last1=Goffee |first1=Rob |last2=Jones |first2=Gareth |title=Leading clever people |journal=Harvard Business Review |date=March 2007 |volume=85 |issue=3 |pages=72–79, 142 |pmid=17348171 |url=https://pubmed.ncbi.nlm.nih.gov/17348171/ |issn=0017-8012}}</ref> There, he helped develop the antibiotic ].<ref name="Greenwood2008"/> In 1977 he left Glaxo and was recruited to the United States by the ], where he worked under ], the Australian immunologist who played an important part in getting the first ], ], licensed.<ref name="WHO2018"/><ref name="Carter2014">{{cite journal |last1=Carter |first1=P. B. |title=George Bellamy Mackaness. 20 August 1922 — 4 March 2007 |journal=Biographical Memoirs of Fellows of the Royal Society |date=2014 |volume=60 |doi=10.1098/RSBM.2014.0017 |url=https://royalsocietypublishing.org/doi/pdf/10.1098/rsbm.2014.0017|page=294|s2cid=71237348 }}</ref> In 1979 Squibb appointed Sykes to lead research into ] ] ].<ref name="WHO2018"/><ref name="Greenwood2008">{{cite book |last1=Greenwood |first1=David |title=Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph |date=2008 |publisher=] |location=Oxford |isbn=978-0-19-953484-5 |page=134 |chapter-url=https://books.google.com/books?id=i4_FZHmzjzwC&dq=Richard+Sykes+glaxo&pg=PA134 |language=en |chapter=4. Wonder drugs}}</ref>
There, he isolated product SQ26.180 from '']'', a bacteria discovered at ].<ref name="Sacharow1982">{{cite news |last1=Sacharow |first1=Fredda |title=Swamp yields a new antibiotic |url=https://www.nytimes.com/1982/06/13/nyregion/swamp-yields-a-new-antibiotic.html |access-date=2 December 2021 |archive-url=https://web.archive.org/web/20211203044147/https://www.nytimes.com/1982/06/13/nyregion/swamp-yields-a-new-antibiotic.html|archive-date=3 December 2021|work=The New York Times |date=13 June 1982}}</ref> By modifying the ] and including a ceftazidime side chain, he produced ], the first monocyclic β-lactam antibiotic.<ref name=Strom2009/><ref name="Sneader2005">{{cite book |last1=Sneader |first1=Walter |title=Drug Discovery: A History |date=2005 |publisher=Wiley |location=Chichester, West Sussex |isbn=978-0-471-89979-2 |page=337 |chapter-url=https://books.google.com/books?id=jglFsz5EJR8C&dq=richard+sykes+aztreonam&pg=PA337 |language=en |chapter=23. Antibiotic analogues}}</ref> In 1981 he coined this new group of antibiotics "monobactam".<ref name="Greenwood2008"/><ref name=Strom2009/> Its potential as a usefulness was published the following year.<ref name="Bryan2012">{{cite book |last1=Fisher |first1=Jed |editor1-last=Bryan |editor1-first=L. |title=Antimicrobial Drug Resistance |date=2012 |publisher=Academic press |location=Orlando |isbn=978-0-12-138120-2 |page=51 |chapter-url=https://books.google.com/books?id=E4FKEj5fMdkC&dq=sykes+ceftazidime&pg=PA51 |language=en |chapter=2. B-Lactams resistant to hydrolysis by the b-lactamases}}</ref> It could treat gram-negative infections such as ] and became the first monobactam to be licensed for clinical use.<ref name="Greenwood2008"/><ref name=Strom2009>{{cite book |last1=Stromgaard |first1=Kristian |last2=Krogsgaard-Larsen |first2=Povl |last3=Madsen |first3=Ulf |title=Textbook of Drug Design and Discovery |date=2009 |publisher=] |isbn=978-1-4200-6322-6 |page=429 |url=https://books.google.com/books?id=YLPMBQAAQBAJ&dq=coined+monobactam&pg=PA429 |language=en}}</ref>


From 1983 to 1986 he was vice-president of infectious and metabolic diseases at Squibb.<ref name="WHO2018"/> He returned to Glaxo in 1987 and succeeded ], almost 30 years after ] acquired ].<ref name="Kap2007">{{cite book |last1=Ravenscraft |first1=David J. |last2=Long |first2=William F. |editor1-last=Kaplan |editor1-first=Steven N. |title=Mergers and Productivity |date=2007 |publisher=] |isbn=978-0-226-42431-6 |pages=306–310 |chapter-url=https://books.google.com/books?id=Smxp09JSwWAC&dq=Richard+Sykes+glaxo+merge+wellcome&pg=PA310 |language=en |chapter=Paths to creating value in pharmaceutical mergers}}</ref> The '']'' noted that at Glaxo, when a group of antibiotics failed in the last stages of clinical trial, Sykes praised the teams that had worked on them and encouraged them to move on.<ref name="Goff2007"/> In 1993 he received his ].<ref name="WHO2018"/>
In 2004 he spearheaded an abortive attempt to merge Imperial College with ].


In 1994, during his time at Glaxo, he was part of the group that founded the ] for research into vaccines.<ref name=MRC1994>{{cite book |title=MRC Annual Report |date=1994 |publisher=Medical Research Council |page=26 |url=https://books.google.com/books?id=eiwgAQAAMAAJ&q=richard+sykes+jenner+institute |language=en}}</ref><ref name=UKV2021>{{cite web |title=The Vaccine Taskforce: objectives and membership of steering group |url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027646/vtf-interim-report.pdf |website=GOV.UK |access-date=30 November 2021 |language=en}}</ref><ref name="Dickson1998">{{cite journal |last1=Dickson |first1=David |title=Research trio to develop new vaccines |journal=Nature Medicine |date=1 December 1998 |volume=4 |issue=12 |pages=1349 |doi=10.1038/3927 |pmid=9846561 |s2cid=33610131 |language=en |issn=1546-170X|doi-access=free }}</ref> In 1995 he oversaw the merger of Glaxo with Wellcome, to form Glaxo-Wellcome.<ref name="Kap2007"/><ref name="Brier2009">{{cite book |last1=Brier |first1=Jennifer |title=Infectious Ideas: U.S. Political Responses to the AIDS Crisis |date=2009 |publisher=] Press |isbn=978-0-8078-3314-8 |page=193 |url=https://books.google.com/books?id=TLuPrFGD7LwC&dq=Richard+Sykes+1995+glaxo+wellcome&pg=PA193 |language=en}}</ref> In 1997, he became chair of Glaxo-Wellcome.<ref name="Gay2013">{{cite book |last1=Gay |first1=Hannah |last2=Scientific (Firm) |first2=World |title=The Silwood Circle: A History of Ecology and the Making of Scientific Careers in Late Twentieth-Century Britain |date=2013 |publisher=] |isbn=978-1-84816-991-3 |page=183 |url=https://books.google.com/books?id=DjW6CgAAQBAJ&dq=richard+sykes+merge+glaxo&pg=PA183 |language=en}}</ref> In 2000 he oversaw the ] and held its chair until 2001.<ref name="Gay2013"/><ref name="Rug2005">{{cite book |last1=Rugman |first1=Alan M. |title=The Regional Multinationals: MNEs and 'Global' Strategic Management |date=2005 |publisher=Cambridge University Press |location=Cambridge |isbn=0-521-84265-4 |page=123 |url=https://books.google.com/books?id=BgDnv2XlssQC&dq=richard+sykes+merge+glaxo&pg=PA123 |language=en}}</ref><ref name="Fuller2009">{{cite book |last1=Fuller |first1=Steve |title=The Sociology of Intellectual Life: The Career of the Mind in and Around Academy |date=2009 |publisher=SAGE |location=Los Angeles |isbn=978-1-4129-2838-0 |page=15 |chapter-url=https://books.google.com/books?id=x_G2dI27xSYC&dq=richard+sykes&pg=PA15 |language=en |chapter=1. Introduction: the place of intellectual life}}</ref> The merger resulted in the marketing of several new drugs.<ref name="Rug2005"/> According to Sykes at the time, "the industry would be transformed by understanding the ]".<ref name="Rug2005"/>
He also controversially supported the lifting of the £3,000 cap on tuition fees and instead allowing the universities to set fees at anything up to £10,000, a proposal opposed by many student-representing societies.


==Royal Institution and others==
In March 2006 his salary became the centre of attention amongst Imperial College staff and students after the students' union newspaper, ], published a front page article highlighting how much he was paid. Sir Richard received a salary £305,000 a year, the second highest among university principals after Professor Laura Tyson, dean of the ].
Sykes was elected a ] (FRS) in 1997.<ref>{{cite web |title=Richard Sykes {{!}} Royal Society |url=https://royalsociety.org/people/richard-sykes-12379/ |website=royalsociety.org |access-date=30 November 2021 |language=en-gb}}</ref><ref name="royal">{{cite web |url=https://collections.royalsociety.org/DServe.exe?dsqIni=Dserve.ini&dsqApp=Archive&dsqDb=Catalog&dsqCmd=show.tcl&dsqSearch=(RefNo==%27EC%2F1997%2F33%27) |title = Library and Archive Catalogue EC/1997/33 Sir Richard Brook|publisher=The Royal Society |location=London}}</ref> In 1994 he became a trustee of the ],<ref name="WHO2018"/> and in 1997 he was appointed senior independent director of ], a position he held until 2008.<ref name="rigb"/>


He was a member of the ] that published an influential report in 1997.{{clarify|date=November 2021}}<ref>{{cite web|title=Higher Education in the learning society: Main Report|url=http://www.educationengland.org.uk/documents/dearing1997/dearing1997.html|archive-url=https://web.archive.org/web/20150211022652/http://www.educationengland.org.uk/documents/dearing1997/dearing1997.html|url-status=dead|archive-date=11 February 2015|website=Education England|access-date=10 February 2015}}</ref>
On July 1st, 2008, he was succeeded as Rectum of Imperial College by Professor ].

==Later career==

===Imperial===
In January 2001, he was appointed ] of ] and completed his tenure in 2008.<ref name="Hea2003">{{cite book |last1=Heaman |first1=Elsbeth |title=St Mary's: The History of a London Teaching Hospital |date=2003 |publisher=Liverpool University Press |location=Montreal|isbn=0-85323-968-1 |chapter=14. Science and strategy; the merger with Imperial College|page=417 |chapter-url=https://books.google.com/books?id=I6bjRiQzFqkC&dq=richard+sykes+merge+imperial&pg=PA417 |language=en}}</ref><ref name="Imp2008">{{cite web |title=Richard Sykes |url=https://www.imperial.ac.uk/media/imperial-college/staff/reporter/public/Reporter193web.pdf |website=Imperial College London |publisher=Imperial College |access-date=9 November 2021 |location=London}}</ref><ref name="Evatt2002">{{cite book |last1=Evatt |first1=M. A. C. |last2=Brodhurst |first2=E. K. |title=Sharing Experience in Engineering Design (SEED 2002) |date=2002 |publisher=John Wiley & Sons |isbn=978-1-86058-397-1 |url=https://books.google.com/books?id=EKYDrsr4ikQC&dq=richard+sykes&pg=PA119 |language=en}}</ref> At Imperial, he was involved in several controversial debates including on issues such as increasing tuition fees, which he favoured.<ref name="ImpAlum2008">{{cite journal |title=A Rector to remember |journal=Imperial Matters: Alumni Magazine |date=2008 |issue=32 |pages=10–13}}</ref> He criticised secondary schools for the quality of the science taught there, and opposed teaching grants being awarded on a per capita basis.<ref name="Imp2008"/><ref name="Gay2007">{{cite book |last1=Gay |first1=Hannah |title=History Of Imperial College London, 1907–2007, The: Higher Education And Research In Science, Technology And Medicine |date=2007 |publisher=Imperial College Press |location=London |isbn=978-1-86094-708-7 |page=604 |chapter-url=https://books.google.com/books?id=bdC6CgAAQBAJ&dq=richard+sykes+merge+imperial&pg=PA604 |language=en |chapter=15. The expanding college, 1985-2001...Part 1: Governance and the medical school mergers}}</ref> In 2002 he proposed to merge Imperial College with ].<ref name="Harte2018">{{cite book |last1=Harte |first1=Negley |last2=North |first2=John |last3=Brewis |first3=Georgina |title=The World of UCL |date=21 May 2018 |url=https://books.google.com/books?id=TLBdDwAAQBAJ&dq=richard+sykes+merge+imperial&pg=PT144 |publisher=UCL Press |isbn=9781787352933 |language=en}}</ref><ref name="opposition">{{cite news|url=https://www.theguardian.com/education/2002/nov/18/highereducation.universitymergers|title=Opposition ends Imperial and UCL merger dream|work=]|date=18 November 2002|access-date=13 April 2021}}</ref> The strength of opposition meant that it did not go through.<ref name="Imp2008"/> He supported the lifting of the £3,000 cap on ] and instead allowing the universities to set their own fees.<ref name="Harte2018"/><ref name="TSO2007">{{cite book |title=The future sustainability of the higher education sector: international aspects, eighth report of session 2006–07, Vol. 2: Oral and written evidence |date=2007 |publisher=The Stationery Office |isbn=978-0-215-03600-1 |page=43 |url=https://books.google.com/books?id=dBSmydnaPvEC&dq=%C2%Arichard+sykes&pg=PA43 |language=en}}</ref>

===UK Stem Cell Foundation===
Sykes chairs the ].<ref name="rigb"/> It was established in 2005.<ref name="Devaney2013">{{cite book |last1=Devaney |first1=Sarah |title=Stem Cell Research and the Collaborative Regulation of Innovation |date=2013 |publisher=Routledge |location=Abingdon, Oxford |isbn=978-0-415-52130-7 |page=39 |url=https://books.google.com/books?id=101WAgAAQBAJ&dq=%22UK+Stem+Cell+Foundation%22&pg=PT39 |language=en}}</ref><ref name=Hansard2005>{{cite web |title=House of Commons Hansard Debates for 7 Mar 2005 (pt 29) |url=https://publications.parliament.uk/pa/cm200405/cmhansrd/vo050307/debtext/50307-29.htm |website=publications.parliament.uk |publisher=Parliament.co.uk |access-date=30 November 2021}}</ref><ref name="Furcht2011">{{cite book |last1=Furcht |first1=Leo |last2=Hoffman |first2=William |title=The Stem Cell Dilemma: The Scientific Breakthroughs, Ethical Concerns, Political Tensions, and Hope Surrounding Stem Cell Research |date=2011 |publisher=Simon and Schuster |isbn=978-1-62872-181-2 |page=230 |url=https://books.google.com/books?id=MjuCDwAAQBAJ&dq=%22UK+Stem+Cell+Foundation%22&pg=PT230 |language=nl}}</ref>

===Other roles===
From 2003 to 2005 he was trustee of the ].<ref name="WHO2018"/> From 2007 to 2011 he was senior independent director and non-executive deputy chairman of ].<ref name="rigb"/><ref name="Bawden2011">{{cite news |last1=Bawden |first1=Tom |title=Sir Richard Sykes: voted out, but not down |url=https://www.theguardian.com/business/2011/jun/10/enrc-richard-sykes-kazakh-mining-firm |access-date=2 December 2021 |work=The Guardian |date=10 June 2011 |language=en}}</ref> In September 2008, he was appointed chair of ], but resigned in May 2010 over the decision of the ] to halt former health minister ]'s planned reorganisation of health care in London.<ref name=Ramesh2010>{{cite news|url=https://www.theguardian.com/uk/2010/may/26/nhs-london-richard-sykes-resigns|title=NHS London chief Richard Sykes resigns in care review row|author=Randeep Ramesh|work=The Guardian|date=26 May 2010|access-date=27 May 2010}}</ref><ref name="Wise2010">{{cite journal |last1=Wise |first1=Jacqui |title=BMJ News |journal=British Medical Journal |date=5 June 2010 |volume=340 |pages=1216–1217 |url=https://www.bmj.com/bmj/section-pdf/186576?path=/bmj/340/7758/News.full.pdf}}</ref>

Between 2010 and 2012 he was on the advisory board of the ].<ref name="rigb"/> Until 2013, he was vice-chair at the Swiss life sciences company ].<ref name="rigb">{{cite web |title=Sir Richard Sykes (1942–) |url=https://www.rigb.org/our-history/people/s/richard-sykes |website=www.rigb.org |language=en}}</ref><ref> {{webarchive |url=https://web.archive.org/web/20110528004344/http://www.enrc.com/en-GB/About-Us/Management1/Management/ |date=28 May 2011 }}</ref> He was appointed chairman of the ] in 2010 and ] in 2012.<ref name="WHO2018"/> He was appointed ] of ] in 2013.<ref> {{webarchive|url=https://web.archive.org/web/20140514021613/http://www.brunel.ac.uk/news-and-events/news/news-items/ne_289414 |date=14 May 2014 }}</ref> In 2020, Sykes stepped down as chairman of the NetScientific Group after serving it for nine years.<ref name=NetSc>{{cite web |title=Board Changes |url=https://netscientific.net/2020/03/31/2268-2-3/ |website=NetScientific |access-date=9 November 2021 |date=31 March 2020|archive-url=https://web.archive.org/web/20211109193609/https://netscientific.net/2020/03/31/2268-2-3/|archive-date=9 November 2021}}</ref>

===Vaccine Taskforce===
In 2020 he led an independent review of the workings of the Vaccine Taskforce.<ref name="GOV.UK2021"/><ref name=medscape>{{cite web |title=UK COVID-19 Update: Nurse Gives 'Historic' Jab, Oxford Vaccine Phase 3 Results |url=https://www.medscape.com/viewarticle/942175#vp_3|archive-url=https://web.archive.org/web/20210116174907/https://www.medscape.com/viewarticle/942175|archive-date=16 January 2021|website=Medscape |access-date=12 November 2021 |language=en|url-access=subscription}}</ref> On 14 June 2021, Sykes was appointed chair of the ], where he will be responsible for overseeing the delivery of the ], including preparations for booster programmes and encouraging vaccine innovation in the UK.<ref name="GOV.UK2021">{{cite web |title=Sir Richard Sykes appointed chair of Vaccine Taskforce |url=https://www.gov.uk/government/news/sir-richard-sykes-appointed-chair-of-vaccine-taskforce |website=GOV.UK |access-date=25 October 2021 |archive-url=https://web.archive.org/web/20210913015543/https://www.gov.uk/government/news/sir-richard-sykes-appointed-chair-of-vaccine-taskforce |archive-date=13 September 2021 |language=en}}</ref>


==Other activities== ==Other activities==
Sykes was chairman of the advisory panel of the think-tank ].<ref>{{cite web|title=Tax cuts, yes, but first reform public services. Daily Telegraph 3 September 2006 |url=https://www.telegraph.co.uk/comment/personal-view/3631903/Tax-cuts-yes-but-first-reform-public-services.html}}</ref> He is a member of the Advisory Council for the ].<ref name="CaSE Advisory Council">{{cite web|url=http://www.sciencecampaign.org.uk/about/who/advisory.htm |title=Advisory Council of the Campaign for Science and Engineering |access-date=11 February 2011 |url-status=dead |archive-url=https://web.archive.org/web/20100828110110/http://www.sciencecampaign.org.uk/about/who/advisory.htm |archive-date=28 August 2010 }}</ref> He is chair of the Trustees at ].<ref name="KEVII">{{cite web |title=Our Team |url=https://www.kingedwardvii.co.uk/about-king-edward-vii/team |website=King Edward VII's Hospital |access-date=25 October 2021|archive-url=https://web.archive.org/web/20220516172808/https://www.kingedwardvii.co.uk/about-king-edward-vii/team|archive-date=16 May 2022}}</ref>
Sir Richard is chairman of the think-wank ]. He is a trustee of the ] (London) and the ].


==Awards and honours==
In September 2008 he was appointed Chair of ].
Sykes was ] in the ].<ref name="WHO2018"/><ref name="brunel"> {{webarchive|url=https://web.archive.org/web/20160303235940/http://www.brunel.ac.uk/about/people/honorary-graduates/honorary-graduates-1994/sir-richard-sykes-dsc |date=3 March 2016 }}</ref>


He holds ]s from several universities including ], ], ], ], ], ], ], ], ], ], ], ], ], ], ], ], ] and ]. Sykes was elected a ] (FMedSci) in 1998.<ref> – website of the Academy of Medical Sciences</ref>

{{start box}}
In 2009 he received the ] ] and delivered its accompanying lecture.<ref name="Garrod">{{cite web|date=2021|title=Garrod Lecture & Medal|url=https://bsac.org.uk/what-we-do/garrod-lecture-medal/|url-status=live|archive-url=https://web.archive.org/web/20211102031240/https://bsac.org.uk/what-we-do/garrod-lecture-medal/|archive-date=2 November 2021|access-date=2 November 2021|website=The British Society for Antimicrobial Chemotherapy|language=en}}</ref> It was titled "The evolution of antimicrobial resistance: a Darwinian perspective" and was published in the '']'' in 2010.<ref name=Syk2010>{{cite journal |last1=Sykes |first1=R. |title=The 2009 Garrod Lecture: The evolution of antimicrobial resistance: a Darwinian perspective |url=https://academic.oup.com/jac/article/65/9/1842/718974|journal=Journal of Antimicrobial Chemotherapy |date=1 September 2010 |volume=65 |issue=9 |pages=1842–1852 |doi=10.1093/jac/dkq217|pmid=20573657 |doi-access=free }}</ref>

==Selected publications==
===Articles===
*{{Cite book | doi = 10.1016/S0065-2911(08)60376-8| chapter = The β-Lactamases of Gram-Negative Bacteria and their Possible Physiological Role| title = Advances in Microbial Physiology Volume 9| volume = 9| pages = 31–88| series = Advances in Microbial Physiology| year = 1973 | pmid = 4581138| isbn = 978-0-12-027709-4| last1 = Richmond| first1 = M.H.| last2 = Sykes| first2 = R.B.}} (Co-author)
*{{Cite journal | doi = 10.1038/291489a0| pmid = 7015152| title = Monocyclic β-lactam antibiotics produced by bacteria| journal = Nature| volume = 291| issue = 5815| pages = 489–91| year = 1981| bibcode = 1981Natur.291..489S| s2cid = 4303108| last1 = Sykes| first1 = R. B.| last2 = Cimarusti| first2 = C. M.| last3 = Bonner| first3 = D. P.| last4 = Bush| first4 = K.| last5 = Floyd| first5 = D. M.| last6 = Georgopapadakou| first6 = N. H.| last7 = Koster| first7 = W. H.| last8 = Liu| first8 = W. C.| last9 = Parker| first9 = W. L.| last10 = Principe| first10 = P. A.| last11 = Rathnum| first11 = M. L.| last12 = Slusarchyk| first12 = W. A.| last13 = Trejo| first13 = W. H.| last14 = Wells| first14 = J. S.}} (Co-author)
*{{Cite journal | doi = 10.1128/AAC.22.3.414| pmid = 6982680| title = Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria| journal = Antimicrobial Agents and Chemotherapy| volume = 22| issue = 3| pages = 414–20| year = 1982 | pmc=183759| last1 = Bush| first1 = K.| last2 = Freudenberger| first2 = J. S.| last3 = Sykes| first3 = R. B.}} (Co-author)
*{{cite journal |title=Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria |journal=Antimicrobial Agents and Chemotherapy |date=January 1982 |volume=21 |issue=1 |pages=85–92 |doi=10.1128/AAC.21.1.85 |pmid=6979307 |issn=0066-4804|last1=Sykes |first1=R. B. |last2=Bonner |first2=D. P. |last3=Bush |first3=K. |last4=Georgopapadakou |first4=N. H. |pmc=181833 }} (Co-author)
*{{cite journal |title=Penicillin: from discovery to product |journal=Bulletin of the World Health Organization |date=2001 |volume=79 |pages=778–779 |s2cid=33582904 |pmid=11545336 |url=https://www.scielosp.org/pdf/bwho/v79n8/v79n8a16.pdf |language=en |issn=0042-9686|last1=Sykes |first1=R. |issue=8 |pmc=2566502 }}
*{{cite journal |title=The 1998 Radcliffe Lecture. Medicines, Morals and Money: the high ground and the bottom line |journal=Business Ethics: A European Review |date=1999 |volume=8 |issue=2 |pages=79–87 |doi=10.1111/1467-8608.00132 |pmid=11657843 |url=https://onlinelibrary.wiley.com/doi/abs/10.1111/1467-8608.00132 |language=en |issn=1467-8608|last1=Sykes |first1=R. }}
*{{cite journal |title=The 2009 Garrod Lecture: The evolution of antimicrobial resistance: a Darwinian perspective |url=https://academic.oup.com/jac/article/65/9/1842/718974|journal=Journal of Antimicrobial Chemotherapy |date=1 September 2010 |volume=65 |issue=9 |pages=1842–1852 |doi=10.1093/jac/dkq217|last1=Sykes|first1=R.|pmid=20573657|doi-access=free }}

===Books===
*{{cite book |title=New Medicines: The Practice of Medicine and Public Policy |url=https://www.nuffieldtrust.org.uk/research/new-medicines-the-practice-of-medicine-and-public-policy|date=2000 |isbn=978-0-1170-2676-6|publisher=The Nuffield Trust}}

===Reports===
*{{cite book |title=UK Vaccine Taskforce 2020 Achievements and Future Strategy |date=December 2020 |publisher=Gov.UK |url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027646/vtf-interim-report.pdf}}

== References ==
{{reflist}}

==External links==
*{{Scopus|id=7101991075}}

{{s-start}}
{{s-aca}}
{{succession box {{succession box
| title = ] of ] | title = ]
| years = 2000&ndash;2008 | years = 2000–2008
| before = ] | before = ]
| after = ] | after = ]
}} }}
{{end box}} {{succession box
| title = ]
| years = 2013–present
| before = ]
| after = Incumbent
}}
{{s-end}}

{{Imperial College London}}
{{Brunel University}}
{{FRS 1997}}
{{Authority control}}


{{DEFAULTSORT:Sykes, Richard}} {{DEFAULTSORT:Sykes, Richard}}
] ]
] ]
] ]
] ]
] ]
] ]
]
]
]
] ]
] ]
] ]
]

]
]
]
]
]
]
]
]
]

Latest revision as of 09:42, 7 October 2024

British microbiologist (born 1942)

SirRichard SykesFRS FMedSci HonFREng
BornRichard Brook Sykes
(1942-08-07) 7 August 1942 (age 82)
Huddersfield, West Yorkshire, England
Education
Known for
Awards
Scientific career
Fields
Institutions
Chair of the Vaccine Taskforce
Incumbent
Assumed office
2021

Sir Richard Brook Sykes FRS FMedSci HonFREng (born 7 August 1942) is a British microbiologist, the chair of the Royal Institution, the UK Stem Cell Foundation, and the trustees at King Edward VII's Hospital, and chancellor of Brunel University. As of June 2021, he is chair of the UK's Vaccine Taskforce, where he is responsible for overseeing the delivery of the COVID-19 vaccination programme, including preparations for booster programmes and encouraging vaccine innovation in the UK.

In 1972, after gaining a first class bachelor's degree and a doctorate, both in microbiology, Sykes was appointed head of the Antibiotic Resistance Unit at Glaxo, where he helped develop the antibiotic ceftazidime. Subsequently, he was recruited by the Squibb Institute, in the United States, where he then developed aztreonam, the first clinically effective monobactam, a term he coined in 1981 to describe a new group of monocyclic β-lactams produced by bacteria. He oversaw the merger of Glaxo with Wellcome, to form Glaxo-Wellcome in 1995 and became its chair two years later. He then oversaw the Glaxo Wellcome and SmithKline Beecham merger and held its chair until 2001.

His other appointments have included being rector of Imperial College from 2001 to 2008, chairman of NHS London from December 2008 to July 2010, vice-chairman of Lonza Group until 2013, and chairman of Imperial College Healthcare from 2012 to 2018.

Early life and education

Richard Sykes was born in the outskirts of Huddersfield, in West Yorkshire, on 7 August 1942 to Eric Sykes and his wife Muriel Mary Sykes. He attended Royds Hall Grammar school. Prior to his A-levels and completing school, he took up a job as a technician in a pathology laboratory. After leaving secondary school he attended Paddington Technical College and Chelsea College, and gained a place at Queen Elizabeth College where he was awarded a first class BSc degree in microbiology. He received his doctorate in 1972 with a thesis on β-lactamases of Pseudomonas aeruginosa, from the University of Bristol, where he worked with Mark Richmond. In 1973, together, they reported the first β-lactamase classification scheme.

Glaxo and Squibb

GlaxoSmithKline Headquarters

In 1972 Sykes was appointed head of the Antibiotic Resistance Unit at Glaxo. There, he helped develop the antibiotic ceftazidime. In 1977 he left Glaxo and was recruited to the United States by the Squibb Institute for Medical Research, where he worked under George B. Mackaness, the Australian immunologist who played an important part in getting the first ACE inhibitor, captopril, licensed. In 1979 Squibb appointed Sykes to lead research into monocyclic β-lactam antibiotics. There, he isolated product SQ26.180 from Chromobacterium violaceum, a bacteria discovered at Pine Barrens. By modifying the amide side chain and including a ceftazidime side chain, he produced aztreonam, the first monocyclic β-lactam antibiotic. In 1981 he coined this new group of antibiotics "monobactam". Its potential as a usefulness was published the following year. It could treat gram-negative infections such as gonorrhoea and became the first monobactam to be licensed for clinical use.

From 1983 to 1986 he was vice-president of infectious and metabolic diseases at Squibb. He returned to Glaxo in 1987 and succeeded David Jack, almost 30 years after Glaxo acquired Allen & Hanburys. The Harvard Business Review noted that at Glaxo, when a group of antibiotics failed in the last stages of clinical trial, Sykes praised the teams that had worked on them and encouraged them to move on. In 1993 he received his DSc.

In 1994, during his time at Glaxo, he was part of the group that founded the Jenner Institute for research into vaccines. In 1995 he oversaw the merger of Glaxo with Wellcome, to form Glaxo-Wellcome. In 1997, he became chair of Glaxo-Wellcome. In 2000 he oversaw the Glaxo Wellcome and SmithKline Beecham merger and held its chair until 2001. The merger resulted in the marketing of several new drugs. According to Sykes at the time, "the industry would be transformed by understanding the human genome".

Royal Institution and others

Sykes was elected a Fellow of the Royal Society (FRS) in 1997. In 1994 he became a trustee of the Natural History Museum, London, and in 1997 he was appointed senior independent director of Rio Tinto plc, a position he held until 2008.

He was a member of the National Committee of Inquiry into Higher Education that published an influential report in 1997.

Later career

Imperial

In January 2001, he was appointed rector of Imperial College London and completed his tenure in 2008. At Imperial, he was involved in several controversial debates including on issues such as increasing tuition fees, which he favoured. He criticised secondary schools for the quality of the science taught there, and opposed teaching grants being awarded on a per capita basis. In 2002 he proposed to merge Imperial College with University College London. The strength of opposition meant that it did not go through. He supported the lifting of the £3,000 cap on tuition fees and instead allowing the universities to set their own fees.

UK Stem Cell Foundation

Sykes chairs the UK Stem Cell Foundation. It was established in 2005.

Other roles

From 2003 to 2005 he was trustee of the Royal Botanic Gardens, Kew. From 2007 to 2011 he was senior independent director and non-executive deputy chairman of Eurasian Natural Resources Corporation. In September 2008, he was appointed chair of NHS London, but resigned in May 2010 over the decision of the Cameron Ministry to halt former health minister Ara Darzi's planned reorganisation of health care in London.

Between 2010 and 2012 he was on the advisory board of the Virgin Group. Until 2013, he was vice-chair at the Swiss life sciences company Lonza AG. He was appointed chairman of the Royal Institution in 2010 and Imperial College Healthcare in 2012. He was appointed Chancellor of Brunel University in 2013. In 2020, Sykes stepped down as chairman of the NetScientific Group after serving it for nine years.

Vaccine Taskforce

In 2020 he led an independent review of the workings of the Vaccine Taskforce. On 14 June 2021, Sykes was appointed chair of the Vaccine Taskforce, where he will be responsible for overseeing the delivery of the UK's COVID-19 vaccination programme, including preparations for booster programmes and encouraging vaccine innovation in the UK.

Other activities

Sykes was chairman of the advisory panel of the think-tank Reform. He is a member of the Advisory Council for the Campaign for Science and Engineering. He is chair of the Trustees at King Edward VII's Hospital.

Awards and honours

Sykes was knighted in the 1994 New Year Honours.

He holds honorary degrees from several universities including Birmingham, Brunel, Cranfield, Edinburgh, Hertfordshire, Huddersfield, Hull, Leeds, Leicester, Madrid, Newcastle, Nottingham, Sheffield Hallam, Sheffield, Strathclyde, Surrey, Warwick and Westminster. Sykes was elected a Fellow of the Academy of Medical Sciences (FMedSci) in 1998.

In 2009 he received the British Society for Antimicrobial Chemotherapy's Garrod Medal and delivered its accompanying lecture. It was titled "The evolution of antimicrobial resistance: a Darwinian perspective" and was published in the Journal of Antimicrobial Chemotherapy in 2010.

Selected publications

Articles

Books

Reports

References

  1. Connon, Heather (20 June 2004). "Imperial boss measures up money men". The Guardian. Retrieved 7 August 2023.
  2. ^ Who's Who 2018 (170th ed.). London: Bloomsbury Publishing. 2018. p. 2380. ISBN 978-1-472-93501-4.
  3. Wong, John (6 July 2015) Citation by professor John Wong. National University of Singapore. Honorary degree of science recipient
  4. Fletcher, Winston (2003). "1. Sir Richard Sykes FRS". Beating the 24/7: How Business Leaders Achieve a Successful Work/Life Balance. Chichester: John Wiley & Sons. pp. 31–40. ISBN 0-470-84762-X.
  5. Lawrence, Rebecca N. (15 June 2002). "Sir Richard Sykes contemplates the future of the pharma industry. Interview by Rebecca N Lawrence". Drug Discovery Today. 7 (12): 645–648. doi:10.1016/s1359-6446(02)02305-x. ISSN 1359-6446. PMID 12110238.
  6. Sykes, Richard (September 2010). "The 2009 Garrod lecture: the evolution of antimicrobial resistance: a Darwinian perspective". The Journal of Antimicrobial Chemotherapy. 65 (9): 1842–1852. doi:10.1093/jac/dkq217. ISSN 1460-2091. PMID 20573657.
  7. Cooksey, Robert C. (1998). "13. Mechanisms of resistance to antibacterial agents". In Bittar, Edward (ed.). Microbiology. Greenwich, Connecticut: Elsevier. p. 207. ISBN 1-55938-814-5.
  8. ^ Goffee, Rob; Jones, Gareth (March 2007). "Leading clever people". Harvard Business Review. 85 (3): 72–79, 142. ISSN 0017-8012. PMID 17348171.
  9. ^ Greenwood, David (2008). "4. Wonder drugs". Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. Oxford: Oxford University Press. p. 134. ISBN 978-0-19-953484-5.
  10. Carter, P. B. (2014). "George Bellamy Mackaness. 20 August 1922 — 4 March 2007". Biographical Memoirs of Fellows of the Royal Society. 60: 294. doi:10.1098/RSBM.2014.0017. S2CID 71237348.
  11. Sacharow, Fredda (13 June 1982). "Swamp yields a new antibiotic". The New York Times. Archived from the original on 3 December 2021. Retrieved 2 December 2021.
  12. ^ Stromgaard, Kristian; Krogsgaard-Larsen, Povl; Madsen, Ulf (2009). Textbook of Drug Design and Discovery. CRC Press. p. 429. ISBN 978-1-4200-6322-6.
  13. Sneader, Walter (2005). "23. Antibiotic analogues". Drug Discovery: A History. Chichester, West Sussex: Wiley. p. 337. ISBN 978-0-471-89979-2.
  14. Fisher, Jed (2012). "2. B-Lactams resistant to hydrolysis by the b-lactamases". In Bryan, L. (ed.). Antimicrobial Drug Resistance. Orlando: Academic press. p. 51. ISBN 978-0-12-138120-2.
  15. ^ Ravenscraft, David J.; Long, William F. (2007). "Paths to creating value in pharmaceutical mergers". In Kaplan, Steven N. (ed.). Mergers and Productivity. University of Chicago Press. pp. 306–310. ISBN 978-0-226-42431-6.
  16. MRC Annual Report. Medical Research Council. 1994. p. 26.
  17. "The Vaccine Taskforce: objectives and membership of steering group" (PDF). GOV.UK. Retrieved 30 November 2021.
  18. Dickson, David (1 December 1998). "Research trio to develop new vaccines". Nature Medicine. 4 (12): 1349. doi:10.1038/3927. ISSN 1546-170X. PMID 9846561. S2CID 33610131.
  19. Brier, Jennifer (2009). Infectious Ideas: U.S. Political Responses to the AIDS Crisis. University of North Carolina Press. p. 193. ISBN 978-0-8078-3314-8.
  20. ^ Gay, Hannah; Scientific (Firm), World (2013). The Silwood Circle: A History of Ecology and the Making of Scientific Careers in Late Twentieth-Century Britain. World Scientific. p. 183. ISBN 978-1-84816-991-3.
  21. ^ Rugman, Alan M. (2005). The Regional Multinationals: MNEs and 'Global' Strategic Management. Cambridge: Cambridge University Press. p. 123. ISBN 0-521-84265-4.
  22. Fuller, Steve (2009). "1. Introduction: the place of intellectual life". The Sociology of Intellectual Life: The Career of the Mind in and Around Academy. Los Angeles: SAGE. p. 15. ISBN 978-1-4129-2838-0.
  23. "Richard Sykes | Royal Society". royalsociety.org. Retrieved 30 November 2021.
  24. "Library and Archive Catalogue EC/1997/33 Sir Richard Brook". London: The Royal Society.
  25. ^ "Sir Richard Sykes (1942–)". www.rigb.org.
  26. "Higher Education in the learning society: Main Report". Education England. Archived from the original on 11 February 2015. Retrieved 10 February 2015.
  27. Heaman, Elsbeth (2003). "14. Science and strategy; the merger with Imperial College". St Mary's: The History of a London Teaching Hospital. Montreal: Liverpool University Press. p. 417. ISBN 0-85323-968-1.
  28. ^ "Richard Sykes" (PDF). Imperial College London. London: Imperial College. Retrieved 9 November 2021.
  29. Evatt, M. A. C.; Brodhurst, E. K. (2002). Sharing Experience in Engineering Design (SEED 2002). John Wiley & Sons. ISBN 978-1-86058-397-1.
  30. "A Rector to remember". Imperial Matters: Alumni Magazine (32): 10–13. 2008.
  31. Gay, Hannah (2007). "15. The expanding college, 1985-2001...Part 1: Governance and the medical school mergers". History Of Imperial College London, 1907–2007, The: Higher Education And Research In Science, Technology And Medicine. London: Imperial College Press. p. 604. ISBN 978-1-86094-708-7.
  32. ^ Harte, Negley; North, John; Brewis, Georgina (21 May 2018). The World of UCL. UCL Press. ISBN 9781787352933.
  33. "Opposition ends Imperial and UCL merger dream". The Guardian. 18 November 2002. Retrieved 13 April 2021.
  34. The future sustainability of the higher education sector: international aspects, eighth report of session 2006–07, Vol. 2: Oral and written evidence. The Stationery Office. 2007. p. 43. ISBN 978-0-215-03600-1.
  35. Devaney, Sarah (2013). Stem Cell Research and the Collaborative Regulation of Innovation. Abingdon, Oxford: Routledge. p. 39. ISBN 978-0-415-52130-7.
  36. "House of Commons Hansard Debates for 7 Mar 2005 (pt 29)". publications.parliament.uk. Parliament.co.uk. Retrieved 30 November 2021.
  37. Furcht, Leo; Hoffman, William (2011). The Stem Cell Dilemma: The Scientific Breakthroughs, Ethical Concerns, Political Tensions, and Hope Surrounding Stem Cell Research (in Dutch). Simon and Schuster. p. 230. ISBN 978-1-62872-181-2.
  38. Bawden, Tom (10 June 2011). "Sir Richard Sykes: voted out, but not down". The Guardian. Retrieved 2 December 2021.
  39. Randeep Ramesh (26 May 2010). "NHS London chief Richard Sykes resigns in care review row". The Guardian. Retrieved 27 May 2010.
  40. Wise, Jacqui (5 June 2010). "BMJ News" (PDF). British Medical Journal. 340: 1216–1217.
  41. ENRC Management Archived 28 May 2011 at the Wayback Machine
  42. Sir Richard Sykes appointed Chancellor of Brunel University Archived 14 May 2014 at the Wayback Machine
  43. "Board Changes". NetScientific. 31 March 2020. Archived from the original on 9 November 2021. Retrieved 9 November 2021.
  44. ^ "Sir Richard Sykes appointed chair of Vaccine Taskforce". GOV.UK. Archived from the original on 13 September 2021. Retrieved 25 October 2021.
  45. "UK COVID-19 Update: Nurse Gives 'Historic' Jab, Oxford Vaccine Phase 3 Results". Medscape. Archived from the original on 16 January 2021. Retrieved 12 November 2021.
  46. "Tax cuts, yes, but first reform public services. Daily Telegraph 3 September 2006".
  47. "Advisory Council of the Campaign for Science and Engineering". Archived from the original on 28 August 2010. Retrieved 11 February 2011.
  48. "Our Team". King Edward VII's Hospital. Archived from the original on 16 May 2022. Retrieved 25 October 2021.
  49. Sir Richard Sykes DSc – 1994 Archived 3 March 2016 at the Wayback Machine
  50. Fellow Sir Richard Sykes FRS FMedSci – website of the Academy of Medical Sciences
  51. "Garrod Lecture & Medal". The British Society for Antimicrobial Chemotherapy. 2021. Archived from the original on 2 November 2021. Retrieved 2 November 2021.
  52. Sykes, R. (1 September 2010). "The 2009 Garrod Lecture: The evolution of antimicrobial resistance: a Darwinian perspective". Journal of Antimicrobial Chemotherapy. 65 (9): 1842–1852. doi:10.1093/jac/dkq217. PMID 20573657.

External links

Academic offices
Preceded byRonald Oxburgh Rector of Imperial College London
2000–2008
Succeeded byRoy Anderson
Preceded byJohn Wakeham, Baron Wakeham Chancellor of Brunel University
2013–present
Succeeded byIncumbent
Imperial College London
Academics
Engineering
Medicine
Natural Sciences
other
Campus
People
Student life
History
Related
Affiliates
Brunel University of London
University
People
Student life
Affiliates
Fellows of the Royal Society elected in 1997
Fellows
Foreign
Categories: